Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | DRMA | Common Stock | 3.66K | Aug 12, 2021 | Direct | F1 | |||||
holding | DRMA | Common Stock | 12.2K | Aug 12, 2021 | By Hale Trading Company LP | F1, F9 | |||||
holding | DRMA | Common Stock | 255K | Aug 12, 2021 | By Hale BioVentures LLC | F1, F9 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | DRMA | Stock Option (Right to Buy) | Aug 12, 2021 | Common Stock | 12.2K | $5.74 | Direct | F1 | ||||||
holding | DRMA | Stock Option (Right to Buy) | Aug 12, 2021 | Common Stock | 4.88K | $5.74 | Direct | F1, F2 | ||||||
holding | DRMA | Series 1d Preferred Stock | Aug 12, 2021 | Common Stock | 302K | By Hale BioVentures LLC | F3, F9 | |||||||
holding | DRMA | Series 1a Preferred Stock | Aug 12, 2021 | Common Stock | 250K | By Hale BioVentures LLC | F4, F9 | |||||||
holding | DRMA | Series 1b Preferred Stock | Aug 12, 2021 | Common Stock | 410K | By Hale BioVentures LLC | F5, F9 | |||||||
holding | DRMA | Series 1c Preferred Stock | Aug 12, 2021 | Common Stock | 3.57M | By Hale BioVentures LLC | F6, F9 | |||||||
holding | DRMA | Series 1 Preferred Stock | Aug 12, 2021 | Common Stock | 556K | By Hale BioVentures LLC | F7, F9 | |||||||
holding | DRMA | Series 1a Warrants | Aug 12, 2021 | Common Stock | 62.5K | By Hale BioVentures LLC | F8, F9 |
Id | Content |
---|---|
F1 | Shares reported reflect the 1 for 20.5 stock split effected July 1, 2021 (the "Stock Split"). |
F2 | Options vest in 12 equal monthly installments commencing January 1, 2021. |
F3 | The Series 1d Preferred Stock is convertible into shares of Common Stock at a conversion ratio equal to 80% of the offering price in connection with the Issuer's initial public offering ("IPO"). All shares of Series 1d Preferred Stock will be converted into 44,777 shares of Common Stock of the Issuer upon consummation of the IPO. The conversion ratio reflects the Stock Split. |
F4 | The Series 1a Preferred Stock is convertible into shares of Common Stock in connection with the Issuer's IPO. All shares of Series 1a Preferred Stock will be converted into 12,195 shares of Common Stock of the Issuer upon consummation of the IPO. The conversion ratio reflects the Stock Split. |
F5 | The Series 1b Preferred Stock is convertible into shares of Common Stock in connection with the Issuer's IPO. All shares of Series 1b Preferred Stock will be converted into 20,000 shares of Common Stock of the Issuer upon consummation of the IPO. The conversion ratio reflects the Stock Split. |
F6 | The Series 1c Preferred Stock is convertible into shares of Common Stock in connection with the Issuer's IPO. All shares of Series 1c Preferred Stock will be converted into 174,216 shares of Common Stock of the Issuer upon consummation of the IPO. The conversion ratio reflects the Stock Split. |
F7 | The Series 1 Preferred Stock is convertible into shares of Common Stock in connection with the Issuer's IPO. All shares of Series 1 Preferred Stock will be converted into 27,103 shares of Common Stock of the Issuer upon consummation of the IPO. The conversion ratio reflects the Stock Split. |
F8 | The Series 1a Preferred Warrants are convertible into warrants to purchase Common Stock in connection with the Issuer's IPO. All Series 1a Preferred Warrants will be converted into warrants exercisable at $20.50 per share, to purchase up to 3,048 shares of Common Stock of the Issuer upon consummation of the IPO. The conversion ratio and exercise price reflect the Stock Split. |
F9 | Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Exhibit 24- Power of Attorney